Giulio Paciotti, Ph.D.

Giulio Paciotti, Ph.D. has over 35 years of experience in the field of nanotechnology and medical research. Giulio is currently the Chief Science Officer at Cytimmune Sciences, where they lead the company's R&D and manufacturing efforts. Dr. Paciotti has won multiple grants for their work and has led the development of several therapeutics entering clinical trials. Prior to joining Cytimmune Sciences, they worked as a Consultant/Vice President of Research and Development at Otomagnetics, Inc. from 2018 to 2020. Before that, Dr. Paciotti served as the Vice President of Research and Development at Imagion Biosystems, Inc. from 2016 to 2018, where they led the development of the company's MagSense In Vivo Diagnostic Platform. Giulio was responsible for identifying fundamental characteristics of nanoparticles, generating novel surface chemistries, and establishing analytical programs. Dr. Paciotti also has a long history with CytImmune Sciences, having served as the Chief Science Officer from 1999 to 2016. During their tenure, they spearheaded the development of nanotechnology therapeutic programs and secured significant funding. Additionally, they worked as the Vice President of Research and Development at Assay Research, Inc. from 1988 to 1999, where they patented a research diagnostic technology and initiated R&D on drug delivery using nanoparticles. Dr. Paciotti began their career as a Biologist at the National Institutes of Health in 1985, where their research in immunology and oncology laid the foundation for their future work.

Giulio Paciotti, Ph.D. obtained a Bachelor's Degree in Zoology/Animal Biology from the University of Maryland in 1982. Following this achievement, they pursued a Master's Degree in Cell Biology and Physiology from the same institution, which they completed in 1984. Giulio continued their studies at the University of Maryland and earned a Ph.D. in Cancer Cell Biology in 1994.